Archive: Company News
Company News: World Antibiotics Day: Reduction of infection risk in femoral head fractures by 66% with antibiotic-loaded bone cement from Heraeus
– New study from Great Britain verifies the advantages of antibiotic-loaded bone cement from Heraeus with femoral head fractures
– Older patients with concomitant diseases profit from locally applied antibiotics
Good news for World Antibiotics Day on November 18th. As local substances carriers, antibiotic-loaded bone cements from Heraeus help in the battle against implant-associated infections in orthopaedics and trauma surgery to prevent infection. This is demonstrated by a new randomised study* from Great Britain in which the use of double-loaded antibiotic bone cement following femoral head fracture led to a significant 66% reduction in infection risk with primary hip arthroplasties, as compared with bone cement with only one antibiotic.
Company News: Curetis Announces Positive Top Line Data from U.S. FDA Trial
– Primary endpoint for Unyvero LRT product for lower respiratory tract infections shows overall weighted average sensitivity of 90.2% and overall weighted average specificity of 99.3%
– U.S. FDA submission being prepared
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced top line data from its successfully completed Unyvero U.S. FDA trial. The trial was designed to compare the performance of the Unyvero Instrument Platform and the Unyvero LRT Lower Respiratory Tract Cartridge in detecting lower respiratory tract infections to microbiology culture, the current diagnostic standard of care.
Company News: Curetis to Present at Several Investor and Scientific Conferences in the Fourth Quarter 2016
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced its participation in several major industry conferences in the fourth quarter of 2016. The respective presentations will be made available on the company’s website.
October:
Large & MidCap Event, October 5-6, 2016 – Paris, France: one-on-one meetings.
BIO Investor Forum, October 18-19, 2016 – San Francisco, CA, USA: company presentation and one-on-one meetings.
DKOU 2016 (German Congress of Orthopedics and Traumatology), October 25-28, 2016 – Berlin, Germany: scientific meeting. Exhibition booth Hall 2.2-71. Joint symposium with Heraeus Medical, October 27, 2016, at 1:00 pm, room Berlin 2.
November:
SOFCOT 2016 (Congress of the French Society of Orthopedic Surgery & Traumatology), November 8-11, 2016 – Paris, France: scientific meeting. Exhibition booth no. 5952.
AMP 2016 (Association for Molecular Pathology), November 11-12, 2016 – Charlotte, NC, USA: scientific meeting. Exhibition booth no. T13C.
Jefferies 2016 London Healthcare Conference, November 16-17, 2016 – London, United Kingdom: one-on-one meetings.
Biotech and Money Inv€$tival Showcase, November 18, 2016 – London, United Kingdom: company presentation and one-on-one meetings.
Company News: iOmx Therapeutics raises EUR 40 million in Series A round
– Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures
iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, today announced the closing of a Series A financing round totaling EUR 40 million. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and Merck Ventures.
iOmx focuses on the development of first-in-class cancer therapeutics addressing next-generation immune checkpoints. By systematically screening human tumor cells, the company has already identified a number of new targets and analyzed their mode of action. The proceeds of the financing round will be used to advance several proprietary product candidates up to initial clinical proof-of-concept.
iOmx was founded based on work from the laboratory of oncology expert and co-founder Philipp Beckhove, previously at the German Cancer Research Center, Heidelberg, and now at the RCI Regensburg Center for Interventional Immunology. The company’s innovative screening platform was developed by co-founder Nisit Khandelwal, SVP of Research. Additional co-founders include highly experienced biotech executives and internationally renowned cancer specialists Patrick Baeuerle, Elmar Maier (CBO), and Sebastian Meier-Ewert (CEO).
“The development of checkpoint inhibitors represents a major advance in the treatment of certain cancers. However, despite some truly transformative successes, to date only a minority of patients benefit from existing treatment options. We aim to bring the advances in immuno-oncology to a greater proportion of cancer patients,” said Sebastian Meier-Ewert, CEO of iOmx. “Therefore, we are proud to have attracted such an outstanding international investor base. The round was significantly oversubscribed, highlighting the expectation that immune checkpoint-based cancer therapeutics have great potential for changing the oncology landscape – and iOmx is excellently positioned to play a leading role in this field.”
“We are thrilled to back iOmx, together with such a high profile investor syndicate. The company combines all the key features we are looking for when investing: an exceptional management team, world class science, and a market breaking technology platform that has the potential to build a strong pipeline of proprietary and more efficacious cancer therapeutics,” said Henrijette Richter, Chairwoman of iOmx´ Board of Directors and Partner at Sofinnova Partners.